This invention discloses water soluble anti-cancer agents. The invention more particularly disclosl formate salts and formate hydrate salts of tyrosine kinase inhibitors such as Imatinib, Gefitinib, Erlotinib, Sorafenib, Dasatinib, Sunitinib, Lapatinib, Nilotinib, Vatalanib, Tandutinib and the like falling in similar category with enhanced bioavailability. Cyclodextrin clathrate compounds derived from these salts of the tyrosine kinase inhibitors are also disclosed herein.
